Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aldoxorubicin versus topotecan in relapsed or refractory metastatic small cell lung cancer
2014-002189-64Phase 2Completed
- Sponsor
- LadRx
- Start
- Oct 2014
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of aldoxorubicin in small cell lung cancer (SCLC) (2 arms), sponsored by LadRx. Primary endpoint: Progression-free survival. Started Oct 2014; status: completed.
02
Drugs
aldoxorubicin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2014-002189-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002189-64.